➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKesson
Moodys
Boehringer Ingelheim
Harvard Business School
Medtronic
AstraZeneca

Last Updated: August 8, 2020

DrugPatentWatch Database Preview

SOLIRIS Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Recent Clinical Trials for SOLIRIS

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Assistance Publique - Hôpitaux de ParisPhase 2
Johns Hopkins UniversityPhase 1
Samsung Bioepis Co., Ltd.Phase 3

See all SOLIRIS clinical trials

Recent Litigation for SOLIRIS

Identify key patents and potential future biosimilar entrants

PTAB Litigation
PetitionerDate
Amgen Inc.2019-02-28
Amgen, Inc.2019-02-28
2017-12-20

See all SOLIRIS litigation

Pharmacology for SOLIRIS
Mechanism of ActionComplement Inhibitors

Company Disclosures: US Patents for SOLIRIS

These patents were extracted from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Alexion Pharm SOLIRIS eculizumab INJECTABLE; IV (INFUSION) 125166 001 2007-03-16   Start Trial Alexion Pharmaceuticals, Inc. (Cheshire, CT) 2019-03-12 RX Orphan company
Alexion Pharm SOLIRIS eculizumab INJECTABLE; IV (INFUSION) 125166 001 2007-03-16   Start Trial Alexion Pharmaceuticals, Inc. (New Haven, CT) 2027-03-15 RX Orphan company
Alexion Pharm SOLIRIS eculizumab INJECTABLE; IV (INFUSION) 125166 001 2007-03-16   Start Trial Alexion Pharmaceuticals, Inc. (New Haven, CT) 2027-03-15 RX Orphan company
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Patent Text Search: US Patents for SOLIRIS

These patents were identified by searching patent claims

Supplementary Protection Certificates for SOLIRIS

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C300433 Netherlands   Start Trial PRODUCT NAME: ECULIZUMAB; REGISTRATION NO/DATE: EU/1/07/393/001 20070620
CA 2010 00003 Denmark   Start Trial
SPC/GB10/015 United Kingdom   Start Trial PRODUCT NAME: ECULIZUMAB; REGISTERED: UK EU/1/07/393/001 20070620
10C0016 France   Start Trial PRODUCT NAME: ECULIZUMAB; REGISTRATION NO/DATE: EU/1/07/393/001 20070620
C00758904/01 Switzerland   Start Trial FORMER REPRESENTATIVE: VOSSIUS AND PARTNER, CH
132010901820871 Italy   Start Trial PRODUCT NAME: ECULIZUMAB(SOLIRIS); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/07/393/001, 20070620
SZ 12/2010 Austria   Start Trial PRODUCT NAME: ECULIZUMAB
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Moodys
Johnson and Johnson
Boehringer Ingelheim
Baxter
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.